A Phase 3 clinical trial in Gabon, West Africa, demonstrated that a single-dose combination therapy achieved 93% cure rates in malaria patients, presenting a potential breakthrough in combating drug resistance and treatment non-adherence.
Presented today at the American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting, the study tested a four-drug regimen—sulfadoxine, pyrimethamine, artesunate, and pyronaridine (SPAP)—against Plasmodium falciparummalaria.
This approach addresses two critical challenges: rising drug-resistant malaria and the fact that over one-third of patients fail to complete standard three-day treatments, contributing to resistance development and disease progression.
Trial Design and Patient Enrollment
From May 2024 to October 2025, researchers enrolled over 1,000 patients with uncomplicated malaria in Gabon, half under age 10. Participants were randomized to receive either:
- Experimental arm: Single-dose SPAP combination (539 patients)
- Control arm: Standard six-dose artemether-lumefantrine (AL) regimen over three days (442 patients)
The trial specifically focused on a real-world population in a malaria-endemic region, with 28-day follow-up blood tests monitoring parasitological cure rates.
Key Efficacyand Safety Results
The single-dose therapy demonstrated:
- 93% cure rate at 28 days, comparable to 90% with standard therapy
- No serious adverse events related to the study drugs
- High practicality using existing, affordable drugs already available in African healthcare programs
Notably, the four-drug strategy simultaneously targets multiple vulnerabilities in malaria parasites, reducing the likelihood of resistance development—an approach inspired by successful multidrug therapies for tuberculosis.
Public Health Context and Urgency
Malaria cases and deaths have increased significantly since 2016, with WHO reporting 263 million cases and 597,000 deaths in 2023. The disease disproportionately affects sub-Saharan Africa (95% of global burden) and children under five. Growing resistance to artemisinin-based combination therapies (ACTs) and poor treatment adherence have stalled previous progress against the disease.
Implementation Advantages and Future Directions
The SPAP regimen offers several practical benefits:
- Uses generic drugs already produced in Africa (SP component)
- AP component expected to become generic in early 2026
- Simplified administration enhances adherence
Researchers are collaborating with manufacturers to develop combined capsule/sachet formulations and planning additional trials in Mali, Ghana, Kenya, and Mozambique. ASTMH President Dr. David Fidock noted: “This innovation addresses both drug resistance and adherence challenges—two critical barriers in global malaria control.”
Broader Implications and Bridge Strategy
Lead researcher Dr. Mombo-Ngoma emphasized: “As both a researcher and clinician, I need new options now. This single-dose treatment could bridge the gap while novel compounds still in development become available.”
The approach represents a timely solution that leverages existing infrastructure and drugs to achieve immediate impact in malaria-endemic regions facing rising treatment challenges.
Related topics
